share_log

Bristol-Myers Squibb | 4: Statement of changes in beneficial ownership of securities-Officer Hoch Lynelle

SEC announcement ·  Mar 13 08:04
Summary by Futu AI
On March 10, 2024, Lynelle Hoch, President of Cell Therapy Org. at Bristol-Myers Squibb (BMY), completed a series of transactions involving the company's common stock. Hoch acquired a total of 4,351 shares through the exercise of derivative securities at no cost. On the same day, Hoch disposed of 2,625 shares through various transactions, including the payment of exercise price or tax liability by delivering or withholding securities, with some shares sold at a price of $53.79 each. The total market value of the disposed shares amounted to $70,357.32. After these transactions, Hoch's direct holdings in Bristol-Myers Squibb common stock amounted to 1,726 shares.
On March 10, 2024, Lynelle Hoch, President of Cell Therapy Org. at Bristol-Myers Squibb (BMY), completed a series of transactions involving the company's common stock. Hoch acquired a total of 4,351 shares through the exercise of derivative securities at no cost. On the same day, Hoch disposed of 2,625 shares through various transactions, including the payment of exercise price or tax liability by delivering or withholding securities, with some shares sold at a price of $53.79 each. The total market value of the disposed shares amounted to $70,357.32. After these transactions, Hoch's direct holdings in Bristol-Myers Squibb common stock amounted to 1,726 shares.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.